<DOC>
	<DOCNO>NCT01573702</DOCNO>
	<brief_summary>- Progression free survival locally ablative therapy erlotinib EGFR patient progress EGFR-TKI therapy</brief_summary>
	<brief_title>Stereotactic Radiosurgery Other Local Ablation Then Erlotinib Epidermal Growth Factor Receptor ( EGFR )</brief_title>
	<detailed_description>Primary Objectives - To estimate progression free survival ( PFS ) locally ablative therapy erlotinib EGFR-mutant NSCLC patient progress prior EGFR-TKI therapy Secondary Objectives - To evaluate local control sit previously progressive erlotinib follow SRS follow erlotinib - To estimate overall survival ( OS ) locally ablative therapy erlotinib EGFR-mutant NSCLC patient progress prior EGFR-TKI therapy - To characterize toxicity SRS - To characterize toxicity erlotinib precede SRS Exploratory Objectives - To explore VeriStrat result follow completion SRS associate longer PFS OS re-initiation erlotinib - To explore VeriStat result follow completion SRS associate longer PFS OS re-initiation erlotinib - To explore whether `` poor '' VeriStat signatures every turn `` good '' signature study therapy , explore PFS OS patient whose signature change - To utilize full NMR peak MALDI-TOF generate hypothesis regard alternative signature evaluation novel biomarkers</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Written inform consent 18 year age old Histologically cytologically confirm stge IV EGFRmutant NSCLC History previous response EGFRTKI define RECIST 1.1 criterion Progressive disease follow EGFRTKI therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ marrow function Negative urine serum pregnancy test female patient Patients child must agree adequate contraception Unresolved chronic toxicity great 2 , measure CTCAE v4 Treatment FDA approve experimental cancer treatment follow progression EGFRTKI Any history previous great grade 3 toxicity attributable erlotinib Pregnant lactate female Any previous radiation site plan Stereostatic Radiosurgery History another malignancy Concomitant anticancer therapy , immunotherapy , radiation therapy ( within 4 week ) Evidence severe uncontrolled systemic disease Known hypersensitivity reaction idiosyncrasy erlotinib Psychological , familial , sociological , geographical condition Any condition investigator 's opinion jeopardize compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>EGFR mutant</keyword>
	<keyword>Phase II</keyword>
	<keyword>erlotinib</keyword>
	<keyword>tarceva</keyword>
	<keyword>cyberknife</keyword>
	<keyword>Lineberger</keyword>
</DOC>